Attovia Therapeutics, Inc.

Nasdaq: ATTO

Day 66 public/EARLY PUBLIC/IPO Aug 5, 2026/Biological Products, (No Diagnostic Substances)

$16.21

▼ 0.10 (-0.61%)

LIVE

updated 15h ago

Intelligence Core

OBSERVING

New SEC filing in the last 72 h

Current missionThesis Test · Day 31–90

Test the initial thesis against the first earnings, guidance and execution.

Focus

EarningsGuidanceExecutionInstitutional changes

CAUTIOUSFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence55%

CURRENT THESIS INTERPRETED

Attovia Therapeutics, Inc. is an early public clinical-stage biological products company operating at a net loss with reported revenue and cash on the balance sheet. With 66 days as a public entity, high regulatory risk associated with its clinical-stage sector, and mixed fundamental-to-risk signals, the near-term outlook remains cautious.

Momentum

Price · since IPOLIVE

Yahoo · 47 pts

H $25.55L $16.21Last $16.21

Current ThesisINTERPRETEDLIVE

Why

+Clinical-stage biological products sector classification
+Fundamentals reflect reported revenue, net loss, and available cash on the balance sheet per SEC XBRL filings
+Institutional backing evidenced by 2 Schedule 13D/13G filings

Risks

−Newly public status under 90 days creates elevated volatility and execution uncertainty
−High baseline risk score of 78 driven by clinical-stage sector exposure
−Slight negative 1-day momentum of -0.61%

Catalysts

→Future SEC periodic filings (10-Q updates, 8-K disclosures)
→Subsequent institutional ownership disclosures via Schedule 13D/13G filings

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://attovia.com

VIEW-ONLY

Visit

Capturing attovia.com…

Screenshot of Attovia Therapeutics, Inc.'s official website

SNAPSHOT · live view blocked by site (X-Frame-Options: SAMEORIGIN)

Resolving official website…

Research EnvironmentLIVE

Research environment · $ATTOSEC · market · news

22 evidence items|newest evidence 2d ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 60/100 recomputed from 5 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore OBSERVING · New SEC filing in the last 72 h. Mission: Thesis Test.via Intelligence Core

15h agoOBSERVATIONVERIFIEDLast price $16.21 · -0.61% on the day.via Finnhub quoteVERIFIED

Oct 8, 2026EVIDENCEVERIFIEDForm 3/A filed.via SEC EDGARVERIFIED Oct 8, 2026EVIDENCEVERIFIEDForm 3/A filed.via SEC EDGARVERIFIED Oct 8, 2026EVIDENCEVERIFIEDForm 4/A filed.via SEC EDGARVERIFIED Oct 8, 2026EVIDENCEVERIFIEDForm 4/A filed.via SEC EDGARVERIFIED 11d agoEVIDENCEAttovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026via Yahoo · tier 3, cross-check 11d agoEVIDENCEAttovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026via Benzinga · tier 3, cross-check 17d agoEVIDENCEWas Moderna Stock's Cancer Vaccine Run Visible In Advance?via Yahoo · tier 3, cross-check Sep 2, 2026EVIDENCEVERIFIEDForm 10-Q filed · 10-Q.via SEC EDGARVERIFIED

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-10-08	4/A	Attovia Therapeutics, Inc.	SEC ↗
2026-10-08	4/A	Attovia Therapeutics, Inc.	SEC ↗
2026-10-08	3/A	Attovia Therapeutics, Inc.	SEC ↗
2026-10-08	3/A	Attovia Therapeutics, Inc.	SEC ↗
2026-09-02	10-Q

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics